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Azithromycin persists in fetal 
compartment for 7 days after single 
maternal dose, but may not be at 
adequate concentrations
BACKGROUND: Pharmacokinetic studies to 
guide dosing of azithromycin (AZ) for 
pregnancy specific conditions, such as 
preterm premature rupture of membranes 
(PPROM), and data on accumulation of AZ in 
fetal compartment are lacking
METHODS
• Prospective study of 5 pregnant women 
admitted with PPROM
• 1gram oral azithromycin dose one time 
administered on admission 
• Amniotic fluid collected non-invasively 
from underwear lining pads ad lib
• LCMS/mass spectrometry used to quantify 
AZ concentration
• Luminex multiplex assay used to quantify 
TNFa, IL-1a, IL-1B, IL-6, IL-8, IL-10. 
• Primary outcome: time/concentration 
profile of AZ in AF
MAIN RESULTS
• Mean gestational age was 27.5 ±2.3wk and 
BMI 32.8 ±6.2kg/m2 
• AZ successfully quantified in duplicate, 
coefficient of variation 17%. The lower 
limit of detection and quantitation was 
found to be 1 ng/mL and 10 ng/mL, 
respectively (Figure 1)
• AZ trended down and was <60ng/mL after 
day 3 (Figure 2)
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Figure 2: Azithromycin concentration in amniotic fluid following 1 gram oral maternal dose in 
pregnant patients with preterm premature rupture of membranes. 
Figure 3: Azithromycin concentration was positively 
correlated with IL-8 (r=0.38, p=0.03), IL-1a (r=0.39, 
p=0.03), and IL-1b (r=0.36, p=0.04) in amniotic fluid.
Azithromycin concentration was not correlated with TNFa 
(r=0.30, p=0.07), IL-6 (r= -0.06, p=0.75), or IL-10 (r=0.23, 
p=0.2) concentration in amniotic fluid. 
Figure 1: Representative LCMS chromatogram from 
a) Subject 4, b) Subject 5, and c) AZ-D3 internal standard
Table 1: Azithromycin (AZ) concentration in amniotic 
fluid 1-7 days after a single one gram oral azithromycin 
maternal dose. There were no samples collected 0-24 hours 
for any participants so that data is not available (N/A). 
N= number of participants and n= total number of samples. 
CV: coefficient of variation. IQR: interquartile range
